Head of Investor Relations
Niagen Bioscience, Inc. (NAGE)Equibles does not estimate personal net worth.
Get an email with a short summary when Niagen Bioscience, Inc. publishes a filing, an earnings call transcript or a press release.
Get NAGE alertsBrianna Gerber is recorded as Head of Investor Relations at Niagen Bioscience, Inc. (NAGE). Niagen Bioscience, Inc. reported in an 8-K filed July 16, 2024 that Brianna Gerber resigned as Principal Accounting Officer, effective July 12, 2024. Niagen Bioscience, Inc. reported in an 8-K filed July 16, 2024 that Brianna Gerber resigned as Chief Financial Officer and Principal Accounting Officer, effective July 12, 2024. Niagen Bioscience, Inc. reported in an 8-K filed June 25, 2024 that Brianna Gerber resigned as Chief Accounting Officer, effective July 12, 2024. Equibles holds 6 filed executive changes naming Brianna Gerber; each is listed under recent activity with its source filing. The proxy statement of Niagen Bioscience, Inc. reports total compensation of $450,969 for Brianna Gerber in fiscal 2024, including a base salary of $215,000. Disclosed compensation is on record for 3 fiscal years. Brianna Gerber has spoken on 15 earnings calls across 1 company, most recently for Niagen Bioscience, Inc. on May 8, 2024. Niagen Bioscience, Inc. is classified in the Packaged Foods industry within the Consumer Defensive sector. Other leadership on record at Niagen Bioscience, Inc. includes Robert Fried (CEO and Board Member), Frank Jaksch (Chairman and Board Member), James Lee (CFO and Chief Accounting Officer) and 7 others.
“As previously disclosed, Brianna Gerber resigned from her roles as the Company's Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.”
“As previously disclosed, Brianna Gerber resigned from her roles as the Company's Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.”
“It's a pleasure to speak to our investors, partners and team members who have joined us today.”
“It is a pleasure to speak to our investors, partners and employees who have joined us today. ChromaDex delivered on our full year 2023 financial outlook to investors across all metrics and exceeded our targets for gross margin and G&A expense.”
“Now that we've covered the broader strategic landscape and operational overview, I'm excited to delve into the specifics of our third quarter financial results, which showcase our commitment to balancing top- and bottom-line growth and overall operational discipline.”
“I want to extend my heartfelt appreciation to our investors, partners, and employees for your continued support. I'm excited to share our strong second quarter financial results, which reflect our strategy of balanced top and bottom-line growth and overall operational discipline.”
“It's a pleasure to speak to our investors, partners, and employees who have joined us today.”
2023-01-01–2024-07-12
2023-01-01–2024-07-12
Start not stated–2024-07-12
Packaged Foods · Consumer Defensive
Head of Investor Relations
2023-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Niagen Bioscience, Inc. (NAGE) | Former Chief Financial Officer | $215,000 | $450,969 |
| 2023 | Niagen Bioscience, Inc. (NAGE) | Former Chief Financial Officer | $325,000 | $691,588 |
| 2022 | Niagen Bioscience, Inc. (NAGE) | Former Chief Financial Officer | $269,096 | $842,384 |
